Home Alzheimer’s Disease Amir Goldkorn, MD Discusses Baseline CTC Count as a Prognostic Marker of...

Amir Goldkorn, MD Discusses Baseline CTC Count as a Prognostic Marker of PSA Response and Progression in mCSPC

Data analysis of the SWOG S1216 trial showed that men with undetectable circulating tumor counts (CTCs) were 6.1-fold more likely to have a complete response to hormonal therapy and 3.7-fold more likely to achieve 2-years progression-free survival (PFS), according to study findings presented at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program.

Amir Goldkorn, MD, an associate professor of medicine at the University of Southern California Keck School of Medicine spoke with CancerNetwork about the results of the trial.

 

Transcription:

So, this was a study that was conducted in the context of a large phase III randomized clinical trial called S1216. It’s a trial run by the NCI Southwest Oncology Group, or SWOG, a multicenter study. The PI on the clinical trial aspect is Dr. Neeraj Agarwal of the University of Utah, and in this trial 1200 men were…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Cause of Alzheimer’s disease traced to mutation in common enzyme

submitted by /u/scotsman81 Continue Reading to the Source

Reflections on Living With an Incurable Illness : braincancer

(I’ve checked with the moderators to make sure this is appropriate and a good fit for this subreddit. I'm a very private person, and...

This Foramen Magnum Meningioma almost killed me 18 years ago.

submitted by /u/dkrem Continue Reading to the Source

Patients, Family & Friends, and Healthcare professionals : braincancer

I am currently a PhD student based at the Marie Curie Palliative Care Research Centre at Cardiff University. My PhD is focussed on developing...

Recent Comments